[Pitavastatin and new diabetes development].
Managing dyslipidaemia is central to the management of cardiovascular disease. Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus. However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity. Pitavastatin is a new member of the statin class. And pitavastatin has a number of pleiotropic effects that can reduce inflammation and lipid oxidation, improve endothelial function, reduce the metabolic changes associated with adiposity, and improve glucose metabolism and renal function.